Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — Investor Presentation (October 2026)
27 slides from Hyloris Pharmaceuticals Sa's investor presentation, Oct 13, 2026
Slide 1: Where others stop, we start and add value
Where others stop, we start and add value Reinventing Existing Medicines VFB Soirées – Company Update 13 October 2026 Nice to meet you!
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: Tonight: Three Key Questions
Tonight: Three Key Questions What makes Hyloris different? 1 A smarter approach to develop better medicines Where will our growth come from? 2 Our products, priorities and future opportunities How do we turn progress into shareholder value? 3 Growing revenues, disciplined investment and future miles
Slide 4: Pharma needs faster & more affordable innovation
1 · WHAT MAKES HYLORIS DIFFERENT Pharma needs faster & more affordable innovation The traditional way thousands only a of drug candidates are fraction in the pipeline make it to market worldwide Slow Expensive Risky
Slide 5: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Improve DOSAGE FORM and/or change Repurpose existing medicine for a ROUTE of administration of existing NEW therapeutic INDICATION (use) medicines New Chemical Entity Target to be MORE EFFECTIVE – MORE NEW PRODUCT – NEW FIELD usi
Slide 6: Driving faster innovation
Our Value Proposition: Driving faster innovation Reducing Time-to-Market, Cost & Clinical Burden average Traditional model for NCE’s & Biologics 15years up to Approved molecules Hyloris - model 7 years Reduction time (pre)clinical development Needs of Stakeholders taken into account Leverage public
Slide 7: FDA's 505(b)(2) pathway as the engine
FDA’s 505(b)(2) pathway (or equivalent) as the engine Added value to healthcare system Addressing clear unmet needs Technical feasibility Clear scientific & medical rationale Fast market adoption Approved, well-known molecules ≤ 7 years to market Maximized ROI Defined regulatory pathway Large potent
Slide 8: Asset-light: Hyloris develops, partners commercialise
2 · WHERE DOES GROWTH COME FROM Asset-light: Hyloris develops, partners commercialise Hyloris innovates & Hyloris generates develops revenue Focused team in Liège: 54 Partners manufacture Upfronts, milestones, royalties people, 13 nationalities & profit share & commercialise Formulation, clinical, N
Slide 9: A broad, high-value development portfolio driving sustainable growth
A broad, high – value development portfolio driving sustainable growth Commercial Partnerships (Products Launched) Maxigesic IV (value added / non-opioid analgesic) 30+ products 4 Sotalol IV Podofilox Gel (value added / cardiovascular) (high barrier generic / infectious diseases ) Tranexamic Acid IV
Slide 10: From pipeline to commercial progress
From pipeline to commercial progress MARKETED PRODUCTS NEW PARTNERSHIPS FOCUSED INVESTMENT Growing our revenue base Extending our reach Choosing our priorities • Four products commercialised • Orion: Pantoprazole IV RTU in • Advance programmes with the Europe strongest potential • First royalties an
Slide 11: From Pipeline to Commercialisation
From Pipeline to Commercialisation
Slide 12: Broad, innovative cardiovascular portfolio
Broad, innovative cardiovascular portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Sotalol IV IV Atrial Fibrillation Partnered in the U.S. with AltaThera U.S. Aspirin IV IV Acute Coronary Syndrome WW Milrinone ER Oral
Slide 13: Other value-added portfolio
Other value-added portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Maxigesic® IV IV Post-operative pain Co-development with AFT Pharmaceuticals WW Podofilox Gel Topical Ext. genital/perianal warts Partnered in the U.S
Slide 14: Other value-added portfolio, cont'd
Other value-added portfolio, cont’d Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Injection Equine Gastric Ulcer Syndrome HY-095 (PPI) LAI WW Pantoprazole RTU Injection GERD and EE WW WW ex. U.S. Ondansetron ER Tablet Nausea
Slide 15: What sets us apart: Product Selection – ROI – Risk Profile
What sets us apart: Product Selection – ROI – Risk Profile Center of Excellence ▪ CMO search – efficiency for R&D and Regulatory ▪ Cost development ▪ Impressive KOL network Worldwide ▪ Worldwide partner/distribution ▪ Strategic Insights to indentify unmet medical needs network ▪ Patient-centric appr
Slide 16: Our Product Portfolio: 3 Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS A high-potential product backed A catalyst product building a An early-stage product pending with clinical evidence and strong recurring revenue base at clinical validation: signi
Slide 17: Our Product Portfolio: 3 Strategic Focus Groups for Growth
Our Product Portfolio Product Fiches shared separately on website 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS HY-094 (Iron Deficiency Anemia) Maxigesic® IV HY-083 (Idiopathic Rhinitis) Milrinone ER Sotalol IV HY-095 (Equine Gastric Ulcers) Miconazole DB Podofilox Gel (
Slide 18: What moves next in each group
What moves next in each group MAVERICKS CORE DRIVERS SEEDS but also DISCIPLINE The biggest value step Recurring revenue engine Choosing is also stopping • HY-094 (IV iron): Phase 3 IND • 4 products commercialized • Stopped: XTRAZA® U.S. Phase 3, cleared HY-075, HY-091 • Atomoxetine oral liquid: NDA
Slide 19: HY-094 Ferric for injection
HY-094 Ferric for injection Indication: Iron Deficiency Anemia (IDA) Global Intravenous Iron Drugs Market Size 2023 to 2034 (USD Billion) 9 • Innovative NCE injectable iron therapy designed to overcome limitations of 8 current treatments for better convenience and tolerability 7 • Targeting global i
Slide 20: Alenura
Alenura Indication: Interstitial Cystitis/Bladder Pain Syndrome • Defect in inner lining of the bladder = chronic, recurring discomfort & pain Proven pain reduction in 2 • Alenura 15mL prefilled syringe with a dual mode of action: controlled Ph2 trials • Alkalinised lidocaine: penetrates bladder wal
Slide 21: HY-083 Idiopathic Rhinitis
HY-083 Indication: Idiopathic Rhinitis - chronic rhinitis without a known cause • Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, …) • Impacting quality of life daily (sleep patterns, drowsiness, irritability, poor concentration) • Mo
Slide 22: The turning point is visible in the numbers
3 · SHAREHOLDER VALUE The turning point is visible in the numbers H1 2026 vs H1 2025, € million H1 2025 H1 2026 Revenue, driven by upfront and regulatory milestones. H1 2026 5,6 +56% saw first royalties on 4th commercialized product 4,7 Tranexamic Acid IV RTU 3,8 3,6 3,0 lowest Hy net loss since IPO
Slide 23: A solid financial basis
3 · SHAREHOLDER VALUE A solid financial basis Funding cash runway into €8.7M €0* Intent additional funding confirmed by Comfort cash at 30 June 2026 financial debt Q4 2027 Letter CEO Financial flexibility Stronger governance Extra room to execute while licensing deals bring in Compliance embedded up
Slide 24: Three ways for further growth business potential
3 · SHAREHOLDER VALUE Three ways for further growth business potential Different revenue opportunities — not dependent on a single product Maxigesic IV · Sotalol IV · Tranexamic Acid RTU 1 Grow existing products More sales → potential growth in recurring royalties Atomoxetine oral liquid · Valacyclo
Slide 25: The Hyloris Share
The Hyloris Share 2026 Stijn Van Rompay 28% Thomas Jacobsen 43% Scorpiaux BV Nick Reunbrouck Pieter Van Rompay 12% Other Holders 3% 6% 8% Total number of outstanding voting rights (denominator) 28,000,374 For founders: Based on transparency notifications and latest denominator; Total number of secur
Slide 26: Key takeaways
Key takeaways We make existing medicines better – and turn our pipeline into growing recurring revenue. Proven model Sharper strategy Execution Faster, cheaper, lower risk: ≤ 7 Core Drivers for revenue, +56% revenue, lowest H1 loss years and ~€7M or less per Mavericks for value, discipline since IPO
Slide 27: Value Starts Here
Value Starts Here Hyloris Pharmaceuticals SA - 2026 HQ: Boulevard Patience Et Beaujonc N°3/1 4000 Liège, Belgium +32(0)4 346 02 07 [email protected] [email protected]
Hyloris Pharmaceuticals — Investor Presentation (October 2026) on 6ix